Evidence Updates - Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database including professional commentaries

also:  see PubMed link (abstract w/o commentary) to abstract

BACKGROUND: Treatment of cancer is increasingly more effective but is associated with short and long term side effects. Oral side effects remain a major source of illness despite the use of a variety of agents to prevent them. One of these side effects is oral mucositis (mouth ulcers).

Access Pharmaceuticals receives $700,000 first order for MuGuard product in North America (oral mucositis)

press release: Access Pharmaceuticals, Inc. Presents MuGard Clinical Experience at MASCC Conference - MarketWatch

"MuGard is indicated in Europe for the prevention and management of oral mucositis, and has been used by over 2,000 cancer patients globally. A total of 185 documented patients from various studies utilized MuGard in both prophylactic and curative settings"

MuGard (oral mucositis - U.S.) Access Pharma Initiates US MuGard Sampling Program with Leading Oncology Groups - MarketWatch

"...Sampling efforts for the company include providing large oncology groups with MuGard kits containing six weeks' worth of MuGard therapy for patients undergoing radiation and chemotherapy. Through these oncology groups, Access Pharma initially will provide 500 patients throughout 20 top metropolitan areas full courses of therapy to protect them from oral mucositis."